A Phase 2 study of Carboplatin plus Pemetrexed plus Bevacizumab as first-line therapy for stage3B/4 non-squamous non-small-cell lung cancer

A Phase 2 study of Carboplatin plus Pemetrexed plus Bevacizumab as first-line therapy for stage3B/4 non-squamous non-small-cell lung cancer - A Phase 2 study of Carboplatin plus Pemetrexed plus Bevacizumab as first-line therapy for stage3B/4 non-squamous non-small-cell lung cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005143

Enrollment

Registered

2011-02-26

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Carboplatin and Pemetrexed and Bevacizumab on Day1,every 3 weeks,up to 6 cycles. Achieved disease control without unacceptable toxicity receive Pemetrexed and Bevacizumab on Day1 every 3 weeks, until

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically proven non-squamous non small cell lung cancer 2)Patients with Stage3B/4 or postoperative recurrence NSCLC 3)Chemo-na&iuml;ve patient 4)Age:20 years to less than 75 years 5)ECOG Performance status 0-1 6)Patients who has measurable by RECIST(ver1.1)criteria 7)Patients who has the following periods i.Palliative radiotherapy:1weeks ii.Operation:4weeks iii.Thoracic cavity drainage:2weeks vi.Biopsy with incision,poet custody,and treatment to injury:2weeks v.Aspiration biopsy cytology:1weeks 8)Adequate organ function 9)Life expectancy more than 3 months 10)Signed written informed consent

Exclusion criteria

Exclusion criteria: 1)Uncontrolled infection or Serious medical complications 2)Uncontrolled pleural effusion or ascites 3)Brain metastases 4)Serious disease condition 5)Uncontrolled diabetes mellitus 6)Therapeutic anticoagulopathy 7)Uncontrolled hyper tension 8)Current or previous history of GI perforation 9)interstitial lung disease or fibroid lung 10)history of drug-induced interstitial lung diseas 11)Current or previous history of hemoptysis 12)history of hemoptysis 13)Scheduling operation for examination time 14)Treatment history of carboplatin,pemetrexed,bevacizumab 15)Drug allergens 16)Multiple primary cancer 17)Serious psychiatric illness or psychological symptom 18)Women who are pregnant, lactating or with childbearing potential. 19)Ineligible based on decision of an investigator.

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
Progression-free survival(PFS) Overall survival(OS) Safety	—

Countries

Japan

Contacts

Public ContactYoshiki Ishii

Dokkyo Medical University School of Medicine Pulmonary Medicine and Clinical Immunology

ishiiysk@dokkyomed.ac.jp0282-87-2151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026